Spero Therapeutics, Inc. (SPRO) Free cash flow 2016–2020
Spero Therapeutics, Inc. (SPRO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$86.0MFY2020 · since FY2016: -$29.8M → -$86.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2020 | -$86.0M | -70.9% |
| FY2019 | -$50.3M | -19.7% |
| FY2018 | -$42.1M | -7.5% |
| FY2017 | -$39.1M | -31.4% |
| FY2016 | -$29.8M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SPRO financial trends
SPRO RevenueSPRO Net incomeSPRO Net marginSPRO Gross profitSPRO Gross marginSPRO Operating incomeSPRO Operating marginSPRO Operating cash flowSPRO Capital expendituresSPRO Return on equitySPRO Stock buybacksSPRO Dividends paidSPRO Total assetsSPRO Total liabilitiesSPRO Shareholders’ equitySPRO overview →